Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Oncotargets and Therapy|July 25, 2018
New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumabOlivier Bylicki, Nicolas Paleiron, Gaëlle Rousseau-Bussac, et al.
Bulletin Du Cancer|October 18, 2012
[Supportive cares on thoracic oncology]Gaëlle Rousseau-Bussac, Perrine Crequit, Marie-José Masanes, et al.
Translational Lung Cancer Research|October 21, 2024
Double immune checkpoint inhibitor therapy for unresectable pleural mesothelioma rarely induces hyperprogressive disease: a case reportGaspard Naulleau, Isabelle Monnet, Gaëlle Rousseau-Bussac, et al.
Lung Cancer (Amsterdam, Netherlands)|March 9, 2025
Evaluation of teleguided high-intensity exercise rehabilitation at home before lung-cancer surgery (PREPACHIR Study)Florent Vinas, Hélène Goussault, Laurent Boyer, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2019
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, et al.
Cancers|April 12, 2022
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 StudyRenaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, et al.
Annals of Intensive Care|April 18, 2023
ICU admission for solid cancer patients treated with immune checkpoint inhibitorsAnne-Claire Toffart, Anne-Pascale Meert, Florent Wallet, et al.
Pageof 1